Your browser doesn't support javascript.
loading
Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor-2 high expressing salivary duct carcinomas.
Park, Jong Chul; Ma, T Martin; Rooper, Lisa; Hembrough, Todd; Foss, Robert D; Schmitt, Nicole C; Sawhney, Rishi; Flanders, Aaron; Kang, Hyunseok.
Afiliação
  • Park JC; Department of Medicine, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts.
  • Ma TM; Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Rooper L; Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Hembrough T; NantOmics, Rockville, Maryland.
  • Foss RD; Department of Dermatology, The Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Schmitt NC; Department of Otolaryngology - Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Sawhney R; Bayhealth Cancer Institute, Dover, Maryland.
  • Flanders A; Department of Hematology/Oncology, Naval Medical Center, Portsmouth, Virginia.
  • Kang H; Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland.
Head Neck ; 40(12): E100-E106, 2018 12.
Article em En | MEDLINE | ID: mdl-30478962

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias das Glândulas Salivares / Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Receptor ErbB-2 / Anticorpos Monoclonais Humanizados / Trastuzumab / Docetaxel Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias das Glândulas Salivares / Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Receptor ErbB-2 / Anticorpos Monoclonais Humanizados / Trastuzumab / Docetaxel Idioma: En Ano de publicação: 2018 Tipo de documento: Article